Topical Cyclosporine and Disease Progression
Phase 4
Completed
- Conditions
- Disease ProgressionDisease SeverityStainingSchirmersOSDI
- Interventions
- Registration Number
- NCT00567983
- Lead Sponsor
- Innovative Medical
- Brief Summary
The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Mild to Moderate dry eye symptoms
Exclusion Criteria
- Current use of Restasis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1. Restasis - 2. Endura -
- Primary Outcome Measures
Name Time Method Disease Severity 1 yr
- Secondary Outcome Measures
Name Time Method Staining 1 yr
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Restasis's effect on disease progression in dry eye syndrome?
How does topical cyclosporine compare to standard-of-care treatments for dry eye disease severity and progression?
Are there specific biomarkers that predict response to Restasis in patients with ocular surface disease?
What are the potential adverse events associated with long-term use of Restasis in dry eye management?
What combination therapies involving Restasis and Endura show promise in managing dry eye disease progression?
Trial Locations
- Locations (1)
Lakeside Eye Clinic
🇺🇸Chicago, Illinois, United States
Lakeside Eye Clinic🇺🇸Chicago, Illinois, United States